Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome

NCT04734678 is registered in ClinicalTrials.gov with Ain Shams University as lead sponsor.

NCT NCT04734678
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04734678 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparison of Tocilizumab Versus Tocilizumab/Infliximab in Patients With COVID-19-associated Cytokine Storm Syndrome
Lead sponsor
Ain Shams University
Phase
Observational
Overall status
Completed
Start date
December 1, 2020
Completion date
August 1, 2021
Enrollment
153 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

corona virus infection, covid19, cytokine storm